YVYendry Ventura-Carmenate

Yendry Ventura-Carmenate

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yendry Ventura-Carmenate has a total of 153 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Predicting Non‐Target Neutrophil Collection During HPC (A): Implications for Research Protocols in Apheresis

    by Yandy Marx Castillo‐Aleman, Carlos Agustin Villegas‐Valverde, Yendry Ventura‐Carmenate, Shinnette Lumame, Jay Mary Rose‐Roque, Marlene Cato, Hamda Ali, Ruaa Mousa Ali, Rachely Hernandez‐Corrales, Anil Sarode, et al.

    Neutrophils are unintentionally co‐collected during HPC(A) procedures using mononuclear cell collection protocols. Although non‐target granulocyte co‐collection is generally clinically acceptable, excessive neutrophil content may compromise certain translational research applications. This study aimed to develop a predictive model for neutrophil yield during routine HPC(A). A retrospective single‐center analysis of 377 HPC(A) procedures performed between January 2023 and April 2026 was conducted. Donor demographics, hematological parameters, procedural characteristics, and collection efficiency (CE) metrics were analyzed. Correlations between CE 1 and CE 2 were evaluated using Spearman's rank correlation coefficient. A multivariable linear regression model incorporating pre‐apheresis neutrophil count, processed blood volume (pBV), and neutrophil CE 1 was developed to predict neutrophil apheresis yield. Model performance was assessed using R 2 , RMSE, MAE, Bland–Altman analysis, and 5‐fold cross‐validation. Strong positive correlations were observed between CE 1 and CE 2 for both CD34 + cells ( ρ = 0.836, p < 0.0001) and neutrophils ( ρ = 0.865, p < 0.0001). In contrast, the multivariate regression model demonstrated only modest predictive performance for neutrophil yield ( R 2 = 0.198). Compared with the conventional fixed CE 1 approach, the regression‐based model showed lower RMSE, reduced systematic bias, and improved agreement between predicted and observed neutrophil yields on Bland–Altman analysis. Neutrophil yield during HPC(A) can be estimated using a regression model that integrates pre‐apheresis neutrophil count, pBV, and CE 1 . Although predictive performance remains modest, regression‐based approaches improve estimation accuracy compared with simplified fixed CE models and may support procedural planning and translational research applications involving non‐target granulocyte co‐collection in HPC(A) products.

  • Open Access

    Extended routine lymphocyte immunophenotyping refines individual immune organization across a heterogeneous patient cohort

    by Carlos Agustin Villegas Valverde, Yendry Ventura Carmenate, Vianed Marsan Suarez, Yandy Marx Castillo Aleman, Imilla Casado Hernandez, Rachely Hernandez Corrales

    Routine TBNK immunophenotyping detects the major lymphocyte compartments but may underestimate the biologically relevant variation contributed by less frequent but well‐defined minor lymphocyte subsets. This study evaluated whether extending routine TBNK immunophenotyping with minor lymphocyte subsets provides complementary, analytically retrievable information that improves patient‐level immune stratification beyond clinical diagnosis. In this retrospective cross‐sectional study, peripheral blood immunophenotypes from 159 individuals were analyzed using a standardized workflow of eight DuraClone TBNK markers with manual hierarchical selection and absolute counting on a single platform. Multivariate profiling at the patient level was performed using derived immunophenotypic variables rather than single‐cell event data. Canonical and extended panels were compared using nonparametric tests, PERMANOVA, principal component analysis, UMAP, k‐means clustering, inter/intra distance indices, feature importance analysis, and hierarchical heat maps. Canonical immunophenotyping showed the strongest diagnostic associations for the B cell and CD4+ T cell compartments, while the extended panel identified an additional discriminatory structure, with absolute T double negative counts as the most informative minor lymphocyte subsets. Both panels were significantly associated with diagnostic clustering, but the extended panel showed a broader distribution of variance than the diagnostic panel. Compared with the canonical panel, the extended panel increased the inter/intra distance index (0.369 vs. 0.302, p = 0.0027) and substantially repositioned individuals within the immune space, with 59.1% shifting more than 10 percentiles. The clustering agreement between models was partial (ARI = 0.28; NMI = 0.42), and heat maps revealed continuous immunophenotypic axes with an internal substructure enriched in minor lymphocyte subsets. Extended routine immunophenotyping refines the multivariate representation of peripheral immune organization without requiring additional cytometry markers. Rather than replacing standard TBNK analysis, it complements it by revealing complementary, analytically retrievable information from minor lymphocyte subsets, thereby improving patient‐level stratification and facilitating a more accurate, context‐specific interpretation of immune status.

  • Open Access

    Lentiviral Vectors for CAR-T and Other Cell Therapy Products: A Microbiological and Biosafety Perspective

    by Rene Antonio Rivero-Jimenez, Giselle Rivero-Navea, Dhanya Adukkadukkam, Loubna Abdel Hadi, Fatema M. Al Kaabi, Yendry Ventura-Carmenate, Antonio Alfonso Bencomo-Hernandez

    Chimeric antigen receptor T-cell (CAR-T) therapy represents a transformative yet high-cost immunotherapeutic strategy that has benefited many patients with hematological malignancies and autoimmune diseases. As of January 2025, only a limited number of CAR-T products have received approval by the FDA, EMA, and the NMPA, primarily targeting CD19 or B-cell maturation antigen (BCMA) expressed on cancer cells. The manufacturing of currently approved CAR-T products predominantly relies on lentiviral vectors (LVVs), largely derived from human immunodeficiency virus type 1 (HIV-1). LVVs are favored due to their high transduction efficiency and their ability to stably integrate transgenes into the genomes of both dividing and non-dividing cells, including post-mitotic mammalian cells, an advantage over gamma retroviral vectors, which exhibit limited capacity to transduce non-dividing cells. This review outlines the fundamental biological principles of HIV-derived LVVs, their structure, functional components, and biotechnological applications. It provides a comparative analysis of different viral vectors, an overview of the CAR construct, and a summary of ex vivo CAR-T manufacturing processes. Additionally, emerging in vivo CAR-T approaches are discussed, with reference to clinically approved LVV-based CAR-T products. Emphasis is placed on microbiological perspectives and environmental biosafety. Finally, recent advances in LVV technology are described, providing insight into the production of next-generation CAR-T therapies employing in vivo gene delivery approaches.

  • Open Access

    Towards understanding of NK cell antigenic specificity

    by Maria O. Ustiuzhanina, Irina A. Shagina, Evgeniy Nikitin, Evgeniy Klimuk, Maria Salnikova, Olga V. Britanova, Yendry Ventura-Carmenate, Elena I. Kovalenko, Dmitriy M. Chudakov

    NK cells can form clonal populations demonstrating features of adaptive immunity, including long-term memory and at least partial antigenic specificity. Given the limited individual diversity of activating receptors, the nature of NK cell antigenic specificity remains elusive. To explore this riddle, we combined scRNA-Seq of ex vivo FACS-sorted NK cell subsets expressing specific KIR receptors, single-cell cloning and bulk RNA-Seq of in vitro cultured KIR2DS4⁺ NK cell clones, transcriptomic profiling of antigen-stimulated NK cells, and in silico modeling of glycosylated KIR2DS4-peptide-HLA complexes. scRNA-Seq resolved 12-15 clusters per KIR⁺ subset with highly heterogeneous KIR, KLRC and NCR expression patterns, consistent with clonal lineages. Notably, those clusters demonstrated over 30 differentially expressed glycosyltransferase genes, potentially involved in post-translational modification of NK cell receptors. Single-cell-derived KIR2DS4⁺ cultures exhibited clone-specific cytotoxic, chemokine and KIR receptor genes, and transcriptional differences in > 40 glycosyltransferases. In peptide culturing autologous assays, SARS-CoV-2 (KTFPPTEPK) and EBV (CRAKFKHLL) peptides elicited NK cell proliferation and distinct transcriptional programs linking cytotoxicity genes, KIR2DS4 and glycosyltransferases. Structural modeling revealed that N-linked glycosyl residues in specific regions of KIR2DS4 may alter its contacts and interaction with MHCI and the presented peptide. We conclude that KIR⁺ human NK cells comprise clonally imprinted populations with distinct glycosyltransferase expression profiles, and site-specific KIR2DS4 glycosylation may modulate interaction with peptide-MHCI complexes, suggesting a post-translational layer of clonal NK cell diversification as a clue to their antigenic specificity.

  • Citrate Versus Citrate–Heparin Anticoagulation in HPC (A): Comparative Effects on Intra‐Apheresis Mobilization of CD34 + Hematopoietic Progenitor Cells

    by Yandy Marx Castillo‐Aleman, Carlos Agustin Villegas‐Valverde, Antonio Alfonso Bencomo‐Hernandez, Shinnette Lumame, Charisma Castelo, Jay Mary Rose‐Roque, Marlene Cato, Nameer Al‐Saadawi, Mohamed Ibrahim Abu‐Haleeqa, Aseel Suleiman Alsaid, et al.

    Successful hematopoietic stem cell transplantation relies on the collection of a sufficient number of CD34 + hematopoietic progenitor cells (HPCs). While acid citrate dextrose solution A (ACD‐A) is a common anticoagulant (AC) for HPC apheresis [HPC(A)], recent evidence suggests that concomitant heparin may enhance intra‐apheresis recruitment (IAR) of CD34 + cells and improve collection efficiency. This study aimed to compare citrate‐only and citrate–heparin protocols in routine HPC(A) procedures, with a focus on their effects on IAR and efficiency outcomes. A retrospective analysis was performed on 266 HPC(As) from 193 apheresis donors in autologous and allogeneic settings. Donor demographics, procedural parameters, and collection outcomes were compared between the ACD‐A–only and ACD‐A plus heparin protocols. The study endpoints included apheresis yield (AY/kg), collection efficiencies (CE 1 , CE 2 , and cruCE), recruitment ratio (RR), and performance ratio (PR). Statistical analyses included Mann–Whitney U tests, effect sizes, and partial least squares (PLS) regression. Heparinized procedures demonstrated higher processed total blood volume ratios, lower AC volumes, and superior outcomes across CE 1 (83.8% vs. 72.5%, p = 0.00027), CE 2 (70.8% vs. 64.2%, p = 0.0055), cruCE (77.0% vs. 72.4%, p < 0.0001), RR (2.3 vs. 1.7, p < 0.0001), PR (239.3% vs. 208.2%, p < 0.0001), and AY/kg (6.75 vs. 5.23 × 10 6 CD34 + cells/kg, p = 0.0025). The effect size and PLS analyses confirmed the contribution of heparin as an adjunct AC enhancing multiple apheresis outcomes. In summary, citrate–heparin anticoagulation was found to be a feasible strategy that improved key collection efficiency and IAR metrics during HPC(A).

  • A Practical Method for Inline‐To‐Offline Conversion in Extracorporeal Photopheresis

    by Yandy Marx Castillo‐Aleman, Shinnette Lumame, Charisma Castelo, Jay Mary Rose‐Roque, Marlene Cato, Mutaz Atieh, Michael Onyema, Carlos Agustin Villegas‐Valverde, Antonio Alfonso Bencomo‐Hernandez, Yendry Ventura‐Carmenate

    Extracorporeal photopheresis (ECP) is an established immunomodulatory therapy that is traditionally delivered using either “inline” systems, which integrate mononuclear cell (MNC) collection, photoactivation, and reinfusion, or “offline” platforms that allow greater processing flexibility but require dedicated irradiation equipment. Access to standalone UVA irradiators may be limited in clinical and research settings where cryopreservation of ECP‐treated cells is required. In this study, we describe a practical hybrid approach that adapts the inline Amicus Blue Photopheresis System into an inline‐to‐offline workflow, enabling larger total blood volume processing, partial reinfusion, and cryopreservation of photoactivated MNCs. Using a fixed 200‐mL MNC collection, followed by standard 8‐methoxypsoralen administration and UVA irradiation, 50 mL was reinfused inline, while the remaining product was aliquoted for offline cryopreservation. This method has been implemented in the OPERA clinical trial (NCT05413005) and preserves procedural safety, product integrity, and operational simplicity. In summary, this approach enables offline capabilities within an inline ECP framework without requiring an independent UVA irradiator and expands flexibility for clinical programs and translational research. Trial Registration: NCT05413005.

  • Plasma Separation Efficiency in Double Filtration Plasmapheresis: A Retrospective Study of Patients With Hyperlipidemia

    by Yandy Marx Castillo‐Aleman, Carlos Agustin Villegas‐Valverde, Shinnette Lumame, Jay Mary Rose‐Roque, Charisma Castelo, Marlene Cato, Maysoon Al‐Karam, Ashwag Shamkhi Al Dhuhaibat, Stefano Benedetti, Fatema Mohammed Al‐Kaabi, et al.

    Background: Double filtration plasmapheresis (DFPP) is a membrane‐based apheresis technique that separates plasma components using two sequential filters; it is commonly used to remove high‐molecular‐weight substances across various indications. While various metrics such as “plasma removal efficiency” are well established in therapeutic plasma exchange, “plasma separation efficiency” (PSE) remains unreported in DFPP. This study aims to evaluate PSE across DFPP sessions performed with plasma filters of different pore sizes. Materials and Methods: A retrospective study of DFPP procedures performed in patients with hyperlipidemia at a single center between April and July 2025 was conducted. Patient demographics, laboratory values, and procedural parameters were collected. PSE was calculated with and without hematocrit (HCT) adjustment (PSE 1 and PSE 2 ). Associations with procedural variables were assessed using paired tests and multivariate linear regression. Results: A total of 42 DFPPs were performed in 19 patients using the Inuspheresis system, alternating two plasma fractionators (DFPP‐1 and DFPP‐2 with large and small pore size, respectively). PSE 2 and PSE 1 declined significantly from DFPP‐1 to DFPP‐2 ( p = 0.0002 and p = 0.0014, respectively), with Cohen's d indicating large and moderate‐to‐large effect sizes. DFPP also resulted in significant reductions in total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, lipoprotein(a), and C‐reactive protein. Multivariate models showed that the plasma separation rate and HCT shifts were significantly associated with PSE 2 and PSE 1 during DFPP‐2 but not during DFPP‐1. Conclusions: PSE is a reproducible parameter influenced by membrane pore size and procedural factors. Incorporating PSE monitoring, particularly with HCT adjustment, may support optimization of individualized DFPP protocols in routine apheresis practice.

  • Open Access

    Quality control strategy for differentiating induced pluripotent stem cells into pancreatic β-cells before transplantation

    by Francisco Sotomayor Lugo, Mays Amer Abuhantash, Gisela Maria Suarez Formigo, Sharmin Haideri, Lucia Tomiyama, Grinand Luc, Masaru Niidate, Liping Sun, Nataly Iglesias Barrameda, Tania Grinan Ramirez, et al.

    Type 1 diabetes mellitus (T1DM) is a chronic autoimmune disease characterized by the destruction of pancreatic β-cells and the subsequent loss of insulin production. The regeneration of pancreatic β-cells from induced pluripotent stem cells (iPSCs) represents a promising therapeutic approach for restoring β-cell function in T1DM patients. However, ensuring the safety, functionality, and genetic stability of iPSC-derived β-cells is crucial for their clinical application. To address this challenge, a comprehensive literature review was conducted using PubMed/MEDLINE, Web of Science, and Scopus databases to identify relevant studies published up to October 2025. It included an analysis of key regulatory documents from the U.S. Food and Drug Administration (FDA), the European Medicines Agency on Advanced Therapy Medicinal Products (EMA ATMP), and the International Organization for Standardization (ISO). This article proposes a comprehensive quality control (QC) strategy for differentiating iPSCs into pancreatic β-cells, emphasizing a tiered approach with multiple checkpoints throughout the process. The strategy integrates advanced molecular and functional assays to evaluate cell identity, viability, stability, and microbiological safety. The proposed QC framework allows for continuous monitoring, early detection of potential issues, and real-time adjustments to optimize the differentiation process. The flexibility of this approach ensures its adaptation to emerging scientific advancements and regulatory requirements. This integrated and adaptable QC strategy enhances the likelihood of success in generating functional β-cells, laying a solid foundation for the clinical application of iPSC-derived β-cell therapies and offering hope for effective, long-term treatments for T1DM.

  • Open Access

    Validation of an Optimized DuraClone Phenotyping Kit Workflow for TBNK Subset Quantification

    by Carlos Agustin Villegas‐Valverde, Imilla Casado Hernandez, Yaima Zuñiga Rosales, Fatma Abdou, Shadi Sharif Shamat, Antonio Alfonso Bencomo‐Hernandez, Yendry Ventura‐Carmenate

    Quantification of T‐cells, B‐cells, and NK‐cells assay is crucial for diagnosing and monitoring immune diseases and evaluating lymphodepleting therapies. To standardize and validate an optimized workflow of the Beckman Coulter DuraClone IM Phenotyping Basic Kit for quantification of TBNK subsets in peripheral blood. Procedural changes included the use of an alternative lysis buffer, the addition of counting beads, the elimination of centrifugation steps, and an increase in acquisition volume. Validation followed CLSI H42‐A2 and H62 guidelines, assessing accuracy, precision, linearity, and limit of quantification (LLOQ). Accuracy was evaluated by comparison with Immuno‐Trol controls and by Bland–Altman analysis against standard immunophenotyping methods. External proficiency was assessed through participation in the College of American Pathologists (CAP) TBNK program in 2024. Procedural steps were reduced by 50%, and processing time by 38.6%. The modified method demonstrated high accuracy (−3 < bias < 35; cells/μL), a low bias based on Immuno‐Trol targets, and strong agreement in the Bland–Altman analysis. The method successfully passed three CAP external proficiency tests in 2024, confirming interlaboratory reliability. Coefficients of variation for precision were below 10% for all subsets. Linearity exceeded R 2 > 0.99 across clinically relevant ranges. Most subsets demonstrated an LLOQ below 10–50 cells/μL, which is suitable for clinical applications. The proposed modifications to the DuraClone IM kit protocol improved workflow efficiency and analytical performance without compromising accuracy or reproducibility. The validated method provides a standardized, reliable, and time‐efficient alternative for lymphocyte subset quantification.


  • Double Filtration Plasmapheresis for Environmental Toxin Removal: A Case Series of Patients With Hyperlipoproteinemia(a)

    by Yandy Marx Castillo‐Aleman, Carlos Agustin Villegas‐Valverde, Maysoon Al‐Karam, Shinnette Lumame, Jay Mary Rose‐Roque, Ehab Bawadi, Dina El‐Mouzain, Stefano Benedetti, Yendry Ventura‐Carmenate, Fatema Mohammed Al‐Kaabi, et al.

    Double filtration plasmapheresis (DFPP) is a promising method for removing environmental toxins, but comparative data on toxin‐specific removal patterns remain limited. This study investigates the removal effectiveness of various pollutants in patients with hyperlipoproteinemia(a) undergoing DFPP. We retrospectively analyzed procedures performed using the Inuspheresis System with two filters with differing pore sizes. We assessed the clearance of heavy metals, volatile organic compounds, and organic pollutants by calculating the “ redistribution ratio ” (RR) and the percentage of captured analyte (CA). Analytes with large volumes of distribution and low protein binding, such as toluene, methyl isobutyl ketone, and barium, showed high rebound (RR: 1.95, 1.31, and 1.97, respectively), suggesting redistribution from peripheral compartments. Moderate rebound was observed for partially protein‐bound toxins, including PCB 153 (0.76), PCB 138 (0.74), and hexachlorobenzene (0.66). Low or negative RRs were seen with arsenic (−0.49), mercury (−0.05), and cobalt (0.08), likely reflecting limited redistribution. High CA values were recorded for lipophilic, protein‐bound toxins such as PCBs and p,p′‐DDE. Herein, we demonstrate that DFPP is effective in removing environmental toxins from the human body. The pharmacokinetic properties of each compound are key determinants of DFPP effectiveness and may help guide the development of personalized detoxification strategies to optimize its clinical use.